Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two phenomenal growth stocks that investors probably can’t go wrong with when investing in for the long term. They are leaders in the GLP-1 weight loss space, and have been generating strong growth in recent years.
But while they are similar, the stock I invested in earlier this year was Novo Nordisk. Here’s why I bought it instead of its larger rival, and why I still think Novo is the better buy right now.
Image source: Getty Images.